Galera Therapeutics, Inc.
GRTX
$0.02
$0.00-6.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.31M | 1.05M | 1.87M | 1.70M | 3.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.44M | 1.14M | 1.96M | 1.62M | 3.74M |
| Operating Income | -1.44M | -1.14M | -1.96M | -1.62M | -3.74M |
| Income Before Tax | -1.39M | -1.08M | -1.59M | -4.93M | -5.78M |
| Income Tax Expenses | -- | -- | -- | 0.00 | -203.00K |
| Earnings from Continuing Operations | -1.39M | -1.08M | -1.59M | -4.93M | -5.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.39M | -1.08M | -1.59M | -4.93M | -5.58M |
| EBIT | -1.44M | -1.14M | -1.96M | -1.62M | -3.74M |
| EBITDA | -1.43M | -1.13M | -1.96M | -1.62M | -3.74M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.09 | -0.10 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.04 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.09 | -0.10 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.04 |
| Average Basic Shares Outstanding | 98.50M | 98.50M | 98.50M | 55.36M | 54.39M |
| Average Diluted Shares Outstanding | 98.50M | 98.50M | 98.50M | 55.36M | 54.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |